Cañete R, León LM, Rodríguez L

Language: English
References: 4
Page: 8-8
PDF size: 121.43 Kb.

Text Extraction

To the Editors:

The COVID-19 pandemic has led to collapse of national health systems across the globe, overwhelmed by the imbalance between health care needs and availability of human and material resources. To control and prevent further transmission, Cuba has developed intersectoral strategies in which the biotech industry has been deeply involved.
One of several products destined for COVID-19 control is Nasalferon, a nasally administered recombinant alfa 2b interferon that acts against viral replication. Its use is recommended as a complement to public health measures to reinforce the first line of defense against the virus in the oropharyngeal tract.

REFERENCES

1. Ministry of Public Health (CU). Protocolo de actuación nacional para laCOVID-19. Versión 1.5 [Internet]. Havana: Ministry of Public Health (CU); 2020Aug [cited 2021 Feb 8]. 215 p. Available at: https://fi les.sld.cu/editorhome/files/2020/08/VERSION-5-DEL-PROTOCOLO-PARA-PUBLICAR-13-DE-AGOSTO-2020.pdf. Spanish.

2. Díaz-Canel-Bermúdez M, Núñez-Jover J. Gestión gubernamental y cienciacubana en el enfrentamiento a la COVID-19. An Acad Cienc Cuba. 2020 [cited2021 Feb 8]; 10(2). Available at: http://www.revistaccuba.cu/index.php/revacc/article/view/881. Spanish.

3. Registro Público de Ensayos Clínicos. Farmacodinamia del Nasalferon envoluntarios sanos [Internet]. Havana: National Clinical Trials CoordinatingCenter (CU); 2020 [cited 2021 Feb 8]. Available at: https://rpcec.sld.cu/ensayos/RPCEC00000308-Sp. Spanish.

4. Martínez-Díaz E, Pérez-Rodríguez R, Herrera-Martínez L, Lage-Dávila A, Castellanos-Serra L. La industria biofarmacéutica cubanaen el combate contra la pandemia de COVID-19. An Acad CiencCuba. 2020 [cited 2021 Feb 8]; 10(2). Available at: http://www.revistaccuba.cu/index.php/revacc/article/view/906. Spanish.